Novartis is well on its way to leading a new class of anti-inflammatory treatments, convincing European regulators to recommend approving its injected therapy for psoriasis and putting the company in line for transatlantic launches next year.

…read more

Source: Novartis’ Enbrel beater bounds toward psoriasis approval ahead of the crowd


0 No comments